In SLE, adding dapirolizumab pegol vs. placebo to usual care improved disease activity at 48 wk.

Lafita, Francisco R; Schattner, Ami; ACP Journal Club Editorial Team at McMaster University · Ann Intern Med · 2026

Where this comes from

Record sourced from PubMed, PMID 42673588.
Also identified by DOI 10.7326/ANNALS-26-03185-JC.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

GIM/FP/GP: [Formula: see text] Rheumatology: [Formula: see text].

Read the full text

View on PubMed · Publisher (DOI)